Lupin bags USFDA tentative approval for Dasatinib Tablets; stock jumps ~2%

29 Aug 2022 , 03:22 PM

Lupin Limited (Lupin), in collaboration with Pharmascience Inc., announced that it has received tentative approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Dasatinib Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, to market a generic equivalent of Bristol-Myers Squibb Company’s Sprycel Tablets, 20 mg, 50 mg, 70 mg, 80 mg.

Dasatinib Tablets (RLD Sprycel) has expected annual sales in the United States of USD 1,569 million, as per the IQVIA MAT June 2022.

Lupin is a market leader in the cardiovascular, anti-diabetic, and respiratory sectors, as well as in the anti-infective, gastrointestinal (GI), central nervous system (CNS), and women’s health segments.

At around 3.24 PM, Lupin was trading at Rs662.75 up by 1.52% from its previous closing of Rs652.80 on the BSE. The scrip touched intraday high and low of Rs665.65 and Rs635 respectively.

For feedback and suggestions, write to us at [e-mail]